Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales

Executive Summary

The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.

You may also be interested in...



Will Pfizer/BioNTech And Moderna Stay Atop The COVID-19 Vaccine Market Forever?

BIO CEO panelist Rajeev Venkayya argued that the huge amount of investment in COVID-19 vaccines makes it possible for new players to challenge Comirnaty and Spikevax’s dominance.

InflaRx Picks Outcomes-Based Reimbursement For COVID-19 Drug

The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.

Sales Of BioMarin’s Hemophilia Gene Therapy Move At Glacial Pace

Analysts had forecast Q4 Roctavian sales of $5m-$6m, but they came in shy of $3m, and uptake has not yet come to reflect apparent demand.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel